OncoGenex Pharmaceuticals Resumes Trade – Plummeting 23% on Lung Cancer …

OncoGenex Pharmaceuticals Resumes Trade – Plummeting 23% on Lung Cancer …

The companyÂ's product candidates include Custirsen that is in Phase III clinical development for the treatment in men with metastatic castrate-resistant prostate cancer, as well as in patients with non-small cell lung cancer; and Apatorsen, which is

(Visited 5 times, 1 visits today)
5
Like
Save

Comments

Comments are disabled for this post.